Mangoceuticals, Inc. Announces Upcoming Launch of its Sildenafil Based Mango Flavored Rapid Dissolve ED Product

Dallas, Texas, June 21, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling multiple men’s health and wellness products through a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug, “Mango,”, is pleased to announce the upcoming release of its second Mango ED product leveraging the Company’s existing custom compound alongside Sildenafil, which is the active ingredient found in Viagra.

The launch of the Company’s Sildenafil based Mango ED product is scheduled to be available for purchase online this summer. Like the Company’s currently marketed and sold Tadalafil based Mango ED product, which leverages the same active ingredient found in Cialis, the new Sildenafil-based Mango will still be compounded with Oxytocin and L-Arginine in a tasty Mango-flavored rapid dissolve tablet (RDT) and individually packaged in a master pack of six tablets per package.

“Our intent with the launch of this new product is to establish Mango as a legitimate competitor armed with the biotechnology behind Tadalafil and Sildenafil, both of which are the two runaway winners in the ED space over the past two decades," noted Jacob Cohen, CEO and Co-Founder of MangoRx. “The ED market has already proven to be big enough to accommodate multiple competing products. Some people like Pepsi and others prefer Coca-Cola. Tadalafil and Sildenafil are both effective biotech solutions and we believed it was important to make both options available in order to capture additional market share and not exclude potential customers based on personal preferences.”

Management also notes that Tadalafil and Sildenafil each have their own unique properties, which can lead to different manifest effects among users. For example, Tadalafil has been proven to last longer than Sildenafil due to a half-life more than four times as long. At the same time, Sildenafil may reach full efficacy faster than Tadalafil. But the most important point is that each has cultivated its own sizeable following and both compounds can be effectively integrated into MangoRx's specialty compounded formula.

Management is also very encouraged by the buzz generated through its recently expanded marketing activities.

Cohen concluded, “We are extremely pleased with our recent efforts and sponsorships with Barstool Sports and GaS Digital Networks and we only intend to get more aggressive with our marketing efforts in the upcoming months as we market our new Sildenafil based Mango ED product. There’s a real buzz and it’s growing. That sense should be amplified further by additional new products that we intend to launch in the upcoming months. Overall, it’s an exciting time for the Company, and we have a lot more excitement to come as we continue to focus on taking market share through the further development of innovative product formulas, superior branding, marketing initiatives and product design.”